Cargando…

853. Real-World Persistency of Patients Receiving Tenofovir-Based Pre-Exposure Prophylaxis for the Prevention of HIV Infection in the US

BACKGROUND: Once-daily oral tenofovir-based combinations as pre-exposure prophylaxis (PrEP) have shown to be an effective biomedical HIV prevention strategy for populations at-risk of acquiring HIV-1. However, low adherence can lead to poor effectiveness. This study described the characteristics of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oglesby, Alan, Germain, Guillaume, Laliberte, Francois, Bush, Staci, Swygard, Heidi, MacKnight, Sean, Hilts, Annalise, Duh, Mei Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644701/ http://dx.doi.org/10.1093/ofid/ofab466.1048

Ejemplares similares

1544. HIV Following Oral Pre-Exposure Prophylaxis (PrEP) Initiation
por: Metzner, Aimee A, et al.
Publicado: (2023)

Hospital Admission and Readmission Among US Patients Receiving Umeclidinium/Vilanterol or Tiotropium as Initial Maintenance Therapy for Chronic Obstructive Pulmonary Disease
por: Slade, David, et al.
Publicado: (2021)

Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population
por: Bogart, Michael, et al.
Publicado: (2019)

Impact of adherence to treatment with inhaled corticosteroids/long-acting β-agonists on asthma outcomes in the United States
por: Averell, Carlyne M., et al.
Publicado: (2022)

Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens
por: Priest, Julie, et al.
Publicado: (2023)

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA
por: Laliberté, François, et al.
Publicado: (2020)

Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities
por: Kalhan, Ravi, et al.
Publicado: (2021)

Two years of Truvada for pre-exposure prophylaxis utilization in the US
por: Flash, Charlene, et al.
Publicado: (2014)

Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation
por: Mannino, David, et al.
Publicado: (2022)

Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study
por: Slade, David, et al.
Publicado: (2021)

Structural Basis for the Inhibition of the Autophosphorylation Activity of HK853 by Luteolin
por: Zhou, Yuan, et al.
Publicado: (2019)

Correction to Lancet Rheumatol 2022; 4: e853–63
Publicado: (2023)

Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial
por: Baxi, Sanjiv M., et al.
Publicado: (2018)

853. Epidemiology of Groups A, C, and G β-Hemolytic Streptococcal Pharyngitis
por: Lim, James Ray Mata, et al.
Publicado: (2019)

Real‐World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B‐Cell Lymphoma in the U.S
por: Yang, Xiaoqin, et al.
Publicado: (2021)

Is there a genetic cause of appetite loss?—an explorative study in 1,853 cancer patients
por: Solheim, Tora S., et al.
Publicado: (2012)

Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis
por: Mirembe, Brenda G., et al.
Publicado: (2016)

Pre-Clinical Evaluation of Tenofovir and Tenofovir Alafenamide for HIV-1 Pre-Exposure Prophylaxis in Foreskin Tissue
por: Else, Laura, et al.
Publicado: (2022)

Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US
por: Bogart, Michael, et al.
Publicado: (2023)

Real-World Treatment Patterns and Switching Following Moderate/Severe Chronic Obstructive Pulmonary Disease Exacerbation in Patients with Commercial or Medicare Insurance in the United States
por: Bogart, Michael, et al.
Publicado: (2023)

Tenofovir-Diphosphate in Dried Blood Spots vs Tenofovir in Urine/Plasma for Oral Preexposure Prophylaxis Adherence Monitoring
por: Niu, Xin, et al.
Publicado: (2022)

Drug Synergy of Tenofovir and Nanoparticle-Based Antiretrovirals for HIV Prophylaxis
por: Chaowanachan, Thanyanan, et al.
Publicado: (2013)

Run 853, 26 GeV, 28.6.77, Circulating beams with SFM off
por: Hoffmann, H
Publicado: (1977)

Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate‐Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy
por: Bukkems, Vera E., et al.
Publicado: (2020)

Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
por: Devred, Inès, et al.
Publicado: (2023)

Tenofovir Disoproxil Fumarate-Associated Fanconi Syndrome in an Human Immunodeficiency Virus (HIV)-Uninfected Man Receiving HIV Pre-Exposure Prophylaxis
por: Khan, Soheb, et al.
Publicado: (2017)

Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels
por: Khorana, Alok A., et al.
Publicado: (2020)

Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis
por: Ilomuanya, Margaret O., et al.
Publicado: (2020)

853. Hospital-acquired Infections by Vancomycin-Resistant Enterococcus (VRE): Results in 3 Years of Multicenter Study
por: Tanure, Luciana Coelho, et al.
Publicado: (2020)

PTPN11 c.853T>C (p.Phe285Leu) mutation in Noonan syndrome with chylothorax
por: Watanabe, Daisuke, et al.
Publicado: (2022)

Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide for Human Immunodeficiency Virus Preexposure Prophylaxis at a Boston Community Health Center
por: Marcus, Julia L, et al.
Publicado: (2021)

Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent Prophylaxis with Emtricitabine and Tenofovir
por: García-Lerma, J. Gerardo, et al.
Publicado: (2008)

376. COVID-19 Severity in HIV+ Patients Receiving Tenofovir
por: Homsi, Nora, et al.
Publicado: (2020)

Characterizing Real-World Use Of Tiotropium In Asthma In The USA
por: Averell, Carlyne M, et al.
Publicado: (2019)

Health Care Costs in a Cohort of HIV-Infected U.S. Veterans Receiving Regimens Containing Tenofovir Disoproxil Fumarate/Emtricitabine
por: Nelson, Richard E., et al.
Publicado: (2018)

1551. Changes in Glomerular Filtration Rate after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis
por: Rivera, Adovich, et al.
Publicado: (2023)

Run 853, 27th June 1977, 26 GeV, Measurements with the clearing current monitor in octant 4
por: Gröbner, Oswald, et al.
Publicado: (1977)

Assay method for quality control and stability studies of a new anti-diabetic and anti-dyslipidemic flavone (S002-853)*
por: Naqvi, Arshi, et al.
Publicado: (2015)

Pharmacological therapies for infantile hemangiomas: A clinical study in 853 consecutive patients using a standard treatment algorithm
por: Zhang, Ling, et al.
Publicado: (2016)

Timcodar (VX-853) Is a Non-FKBP12 Binding Macrolide Derivative That Inhibits PPARγ and Suppresses Adipogenesis
por: Hinds, Terry D., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_o4l6moe1m1ic5n2sqcrp7n1cli